News & Events

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s ILT4 mAb with Biosion’s PD-1 mAb.

November 12, 2021

Celldex Presents Positive Preclinical Data from PD- ILT Bispecific Antibody Program CDX- at SITC HAMPTON N J November -- Celldex Therapeutics Inc NASDAQ CLDX today announced positive preclinical data from CDX- the Company s bispecific antibody with dual targeting of ILT and PD- checkpoint [...]

LEARN MORE

Biosion, Inc. Appoints Yao-Yao Zhu, M.D., Ph.D., Head of Global Regulatory Affairs

October 18, 2021

NEWARK Delaware and NANJING China September Biosion Inc announced the appointment of Dr Yao-Yao Zhu as Head of Global Regulatory Affairs Dr Zhu joins Biosion from U S FDA where she served as Medical Officer in the Office of Immunology and Inflammation Office of [...]

LEARN MORE

Biosion, Inc. Raises ¥200M RMB Financing to Support Further Global Development of Its Innovative Pipeline

December 10, 2020

Newark DE Nanjing CN Dec Biosion Inc Biosion today announced completion of Million RMB Million USD of financing to transition Biosion into a clinical stage company within twelve months The financing was led by Lapam Capital joined by Kaiyuan Capital Oceanpine Healthcare Fund C [...]

LEARN MORE

Biosion and ZhenGe Biotech Sign Global Strategic Partnership Agreement Accelerating Biosion’s Innovative Antibody Pipeline for IND Filing

April 11, 2020

NEWARK Delaware USA and NANJING China nbsp April Biosion Inc and Shanghai ZhenGe Biotechnology Co Ltd jointly announced today that the two parties have signed a global strategic partnership agreement to launch multiple projects with Biosion s innovative antibody pipeline and ZhenGe s CDMO [...]

LEARN MORE